San Francisco Sentry Investment Group CA boosted its position in shares of Celgene Corporation (NASDAQ:CELG) by 5.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,671 shares of the biopharmaceutical company’s stock after purchasing an additional 915 shares during the period. Celgene makes up 0.8% of San Francisco Sentry Investment Group CA’s holdings, making the stock its 24th biggest holding. San Francisco Sentry Investment Group CA’s holdings in Celgene were worth $2,295,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. BlackRock Inc. raised its stake in shares of Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after acquiring an additional 3,084,227 shares during the period. Oaktop Capital Management II L.P. purchased a new stake in shares of Celgene in the 2nd quarter valued at approximately $271,605,000. Vanguard Group Inc. raised its stake in shares of Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after acquiring an additional 1,610,056 shares during the period. Harbour Capital Advisors LLC raised its stake in shares of Celgene by 12,913.6% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after acquiring an additional 1,575,074 shares during the period. Finally, Investec Asset Management LTD purchased a new stake in shares of Celgene in the 1st quarter valued at approximately $194,490,000. 80.17% of the stock is currently owned by institutional investors.

Celgene Corporation (NASDAQ:CELG) opened at $102.17 on Thursday. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a market cap of $80,747.23, a P/E ratio of 16.02, a price-to-earnings-growth ratio of 0.79 and a beta of 1.78.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the previous year, the business posted $1.58 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. equities analysts forecast that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

In other Celgene news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares in the company, valued at approximately $12,110,599.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders own 0.95% of the company’s stock.

CELG has been the topic of a number of research analyst reports. Jefferies Group reissued a “buy” rating and issued a $160.00 price target on shares of Celgene in a research note on Friday, September 15th. Mizuho boosted their price target on shares of Celgene from $134.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, September 15th. Vetr downgraded shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price target on the stock. in a research note on Tuesday, August 29th. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene in a research note on Monday, August 28th. Finally, Bank of America reissued a “buy” rating on shares of Celgene in a research note on Wednesday, September 13th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $139.57.

TRADEMARK VIOLATION NOTICE: “San Francisco Sentry Investment Group CA Has $2.30 Million Holdings in Celgene Corporation (CELG)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/07/san-francisco-sentry-investment-group-ca-has-2-30-million-holdings-in-celgene-corporation-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.